Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU3XJP)

Drug Name
Pascolizumab Drug Info
Synonyms SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMU3XJP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Interleukin-4 (IL4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dexpramipexole DM6KXAU Eosinophilic asthma CB02.0 Phase 3 [3]
SAR-156597 DMUICJD Idiopathic pulmonary fibrosis CB03.4 Phase 2 [4]
PEGylated pitrakinra DMBPJ9U Asthma CA23 Phase 2 [2]
Tepoxalin DMVS61L Asthma CA23 Phase 2 [5]
Romilkimab DMYEZ5J Idiopathic pulmonary fibrosis CB03.4 Phase 2 [6]
IL-4R DMYEGRH N. A. N. A. Phase 2 [7]
PF-07264660 DM0GI2H Atopic dermatitis EA80 Phase 1 [8]
PF-07275315 DMHRVUY Atopic dermatitis EA80 Phase 1 [8]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-4 (IL4) TTLGTKB IL4_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7786).
2 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
3 Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
4 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
5 Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30.
6 A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
7 Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70.
8 Clinical pipeline report, company report or official report of Pfizer